|drug3806||conventional oxygen Wiki||1.00|
|drug3928||mechanical ventilation Wiki||1.00|
There is one clinical trial.
The main manifestation of COVID-19 is acute hypoxemic respiratory failure (AHRF). In patients with AHRF, the need for invasive mechanical ventilation is associated with high mortality. Two hypotheses will be tested in this study. The first hypothesis is the benefit of corticosteroid therapy on severe COVID-19 infection admitted in ICU in terms of survival. The second hypothesis is that, in the subset of patients free of mechanical ventilation at admission, either Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) allows to reduce intubation rate safely during COVID-19 related acute hypoxemic respiratory failure.
Description: The time-to-death from all causes within the first 60 days after randomization.Measure: The time-to-death from all causes Time: day-60
Description: the time to need for mechanical ventilation (MV), as defined by any of the 3 criteria for intubation within the first 28 days after randomization.Measure: The time to need for mechanical ventilation (MV) Time: day-28.
Description: The cycle threshold for SARS-CoV-2 PCR at baseline, day 7 and day 10 in samples of the same origin (preferably subglottic i.e. bronchoalveolar lavage or tracheal aspiration, otherwise nasopharyngeal swab)Measure: The viral load in the respiratory tract Time: day-10
Description: Proportion of patients with at least one episode of any healthcare-associated infection between randomization and D28Measure: Number of patient with at least one episode of healthcare-associated infections Time: day-28
Description: To compare the exposition to mechanical ventilationMeasure: Number of days alive without mechanical ventilation Time: day-28
Description: Changes in SOFA (Sepsis-related Organ Failure Assessment) score. (min = 0 for normal status max = 24 for worse status)Measure: Measure of SOFA score Time: day-28
Description: to compare the exposition to renal replacement therapyMeasure: Number of days alive without renal replacement therapy Time: day-28
Description: To compare the lengths of ICUMeasure: Lengths of ICU-stay Time: day-60
Description: To compare the lengths of hospital-stayMeasure: Lengths of hospital-stay Time: day-60
Description: Proportion of patients with severe hypoxemia, which is defined as an oxygen saturation of less than 80% during the same interval during the interval between induction and 2 minutes after tracheal intubationMeasure: Number of patients with severe hypoxemia, Time: day 60
Description: Proportion of patients with cardiac arrest within 1 hour after intubationMeasure: Number of patients with cardiac arrest within 1 hour after intubation Time: day 60
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports